WASHINGTON, D.C.–Differentiating between subgroups of myositis is a diagnostic challenge for physicians, but using some guiding principles can be helpful, an expert said during a session titled, “Muscle Biology, Myositis and Myopathies: Classification, Treatment and Outcome in Idiopathic Inflammatory Myopathies,” here at the 2012 ACR/ARHP Annual Meeting, held November 9–14. [Editor’s Note: This session was recorded and is available via ACR SessionSelect.]
Also by this Author
Ingrid Lundberg, MD, PhD, professor in the rheumatology unit in the department of medicine at Karolinska University Hospital in Solna, Sweden, drew from a collection of cases to offer pointers in sifting through symptoms and made suggestions that might help physicians pin down the nature of a patient’s disease as specifically as possible.
She also reviewed the latest on therapies for myositis, but said there is no “wonder drug” yet.
Patients with elevated creatine kinase (CK) and muscle weakness cannot be assumed to have myositis, she cautioned. “There are other medical conditions that have to be ruled out, and that was recognized already in the diagnostic criteria,” Dr. Lundberg said. The most important alternatives to consider are drug-induced myopathy, infection-induced myopathy, metabolic myopathy, endocrine myopathy, and muscular dystrophy, she said. “These can be excluded by clinical investigations as well as muscle biopsies,” she said.